IMMX (STOCKS)
Immix Biopharma, Inc. Common Stock
$10.920000
-0.450000 (-3.96%)
Prev close: $11.370000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Ilya Rachman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,053.46M
- Employees
- 21
- P/E (TTM)
- -12.92
- P/B (TTM)
- 3.55
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
9
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.18 | $-0.18 | -0.0008 | -0.45% |
|
Mar 2026 (Q1)
|
$-0.18 | $-0.21 | +0.0324 | +15.25% |
|
Dec 2025 (Q4)
|
$-0.28 | $-0.16 | -0.1209 | -75.99% |
|
Sep 2025 (Q3)
|
$-0.24 | $-0.19 | -0.0462 | -23.84% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | $1.93M |
| Operating Expenses | $41.82M |
| Research and Development | $21.62M |
| Other Operating Expenses | $20.19M |
| Operating Income/Loss | -$41.82M |
| Income/Loss From Continuing Operations After Tax | -$39.88M |
| Income/Loss From Continuing Operations Before Tax | -$39.88M |
| Income Tax Expense/Benefit | $33.31K |
| Net Income/Loss | -$39.93M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$39.88M |
| Net Income/Loss Available To Common Stockholders, Basic | -$39.88M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.88 |
| Diluted Earnings Per Share | -$0.88 |
| Basic Average Shares | 93,939,641 |
| Diluted Average Shares | 153,486,680 |
| Assets | $239.11M |
| Current Assets | $233.79M |
| Cash | $232.10M |
| Other Current Assets | $1.69M |
| Noncurrent Assets | $5.32M |
| Fixed Assets | $2.36M |
| Other Non-current Assets | $2.96M |
| Liabilities | $10.19M |
| Current Liabilities | $9.30M |
| Accounts Payable | $5.28M |
| Wages | $173.28K |
| Other Current Liabilities | $3.85M |
| Noncurrent Liabilities | $890.64K |
| Equity | $228.92M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $228.92M |
| Liabilities And Equity | $239.11M |
| Net Cash Flow From Operating Activities | -$38.50M |
| Net Cash Flow From Operating Activities, Continuing | -$38.50M |
| Net Cash Flow From Investing Activities | -$9.15M |
| Net Cash Flow From Investing Activities, Continuing | -$9.15M |
| Net Cash Flow From Financing Activities | $261.52M |
| Net Cash Flow From Financing Activities, Continuing | $261.52M |
| Exchange Gains/Losses | -$20.45K |
| Net Cash Flow | $213.85M |
| Net Cash Flow, Continuing | $213.87M |
| Comprehensive Income/Loss | -$39.86M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$39.93M |
| Other Comprehensive Income/Loss | -$11.61M |
| Other Comprehensive Income/Loss Attributable To Parent | $53.69K |